Talk:Novo (company)

Kasper Kofod 14:49, 14 October 2013 (UTC)

The following section should be cleaned up, and converted into prose before being re-added into the article. All unnecessary and possibly trivial details must be removed. TheOriginalSoni (talk) 17:19, 7 November 2013 (UTC)

Novo Nordisk was created in 1989 through a merger between two Danish companies – Novo Industri A/S and Nordisk Gentofte A/S.

• 1923 Nordisk Insulinlaboratorium (later Nordisk Gentofte) founded by Hans Christian Hagedorn.^[1]
• 1925 Novo Terapeutisk Laboratorium (later Novo Industri) founded.
• 1932 Nordisk Insulinlaboratorium founds the Steno Memorial Hospital.
• 1938 Novo founds Hvidøre Diabetes Sanatorium.
• 1941 Novo launches its first enzyme, trypsin, extracted from the pancreas of animals and used for bating leather before tanning.
• 1946 Nordisk develops isophane insulin, branded as Neutral Protamine Haegdorn or NPH insulin, a neutral insulin with prolonged action.
• 1947 Penicillin Novo is launched – Novo's first product to be manufactured through fermentation.
• 1953 Lente – a long-acting insulin zinc suspension – is launched.
• 1963 Alcalase – Novo's first detergent enzyme produced by fermentation.
• 1973 Nordisk Gentofte markets Nanormon growth hormone for the treatment of growth hormone insufficiency. The growth hormone is extracted from human pituitary glands.
• 1973 Monocomponent (MC) insulin is introduced – the purest insulin available at the time.
• 1974 Novo's B shares are quoted on the Copenhagen Stock Exchange.
• 1977 Trisequens – sequential combined oral hormone replacement therapy (HRT) for peri-menopausal women – is marketed.
• 1977 Novo enters the U.S. insulin market, but based on market share data, the company was a very marginal player.
• 1978 In an effort to alleviate its product and quality problems in the U.S. insulin market, E.R. Squibb & Sons contracts with Novo. Novo becomes the single bulk supplier of insulin for Squibb.
• 1981 Novo becomes the first company in Scandinavia to be quoted on the New York Stock Exchange.
• 1982 Novo enters into a 50/50 U.S. joint venture with E.R. Squibb & Sons, known as Squibb-Novo, based in Princeton, NJ. Squibb-Novo became the distributor for Novo insulin sold in the U.S. market, with Novo focused on producing insulin, and Squibb focused on distributing and selling the product. The joint venture is able to significantly increase Novo's U.S. market share.
• 1982 'Human' Monocomponent insulin is launched in the U.S. – the world's first insulin preparation which is structurally identical to human insulin. It is extracted from the pancreas of pigs and converted to human insulin chemically.
• 1983 Novo Industri A/S enters a joint venture with Canada's Connaught Laboratories, considered to be the birthplace of insulin. Under the terms of the agreement, Novo agreed to manufacture insulin in Canada for distribution by Connaught. Novo Laboratories Ltd. agreed to lease, modernize and operate Connaught's insulin production facilities. Another subsidiary company, Connaught-Novo, was jointly owned by both parent companies. Connought Laboratories was privatized by the Mulroney government in 1985.
• 1985 NovoPen – an injection system similar in appearance to a fountain pen, with replaceable insulin cartridges – is launched.
• 1987 Novo starts production of biosynthetic human insulin with the help of genetically engineered yeast cells using recombinant DNA technology.
• 1988 Nordisk Gentofte markets Norditropin genetically engineered human growth hormone.
• 1989 Novo Industri A/S and Nordisk Gentofte A/S merge to become Novo Nordisk A/S, the world's leading producer of insulin.
• 1989 Following the merger of Novo and Nordisk, and the merger of Bristol-Myers and E.R. Squibb & Sons in the U.S., the Squibb-Novo joint venture in the U.S. market was dissolved. Novo purchased Squibb's 50% share and all rights to the joint U.S. diabetes care business.
• 1989 NovoLet – the world's first prefilled insulin syringe – is marketed.
• 1992 The Steno Memorial Hospital and Hvidøre Hospital merge to form the Steno Diabetes Center.
• 1994 Novo Nordisk Canada Inc. and Connaught Laboratories Ltd. announced a distribution agreement, which replaced their joint venture which was known as Connaught Novo Nordisk Inc. Under the terms of the agreement, Connaught received a financial consideration and a percentage fee for distribution services related to Novo Nordisk Canada's diabetes care products. Connaught continued to distribute Novo Nordisk Canada's diabetes products in Canada and Bermuda.
• 1996 NovoSeven – for the treatment of haemophilia patients with inhibitor reaction – is launched.
• 1998 NovoNorm/Prandin, a new oral treatment for type 2 diabetes, is launched in the US and a number of European countries.
• 1998 Activelle – the first low-dose continuous combined oral HRT for post-menopausal women – is introduced.
• 1999 Novo Nordisk publishes its first social report.
• 1999 Christian Karsten Hansen and Jan Møller Mikkelsen leave Novo Nordisk to found Profound Pharma A/S which is acquired by Maxygen in 2000.
• 1999 Innovo, the world's first insulin doser with a built-in electronic memory, is launched in Europe.
• 1999 Novorapid (Novolog in the U.S.) – a rapid-acting insulin analogue – is marketed.
• 1999 Norditropin SimpleXx – the world’s first liquid growth hormone in a dedicated pen system – is launched.
• 2000 Novofem, a low-dose sequential combined oral HRT, is marketed in Germany. Two years later it is launched in several other European countries.
• 2000 Novo Nordisk is split into three separate companies operating under the umbrella of the Novo Group: Novo Nordisk A/S, Novozymes A/S and Novo A/S.
• 2001 InnoLet – the first insulin delivery system specially designed to suit the needs of insulin users with poor eyesight and reduced dexterity – is launched.
• 2001 InDuo – the world's first combined blood glucose monitor and insulin injection system – is introduced.
• 2001 NovoRapid/Novolog FlexPen and Insulatard (NPH) FlexPen are marketed. FlexPen is a new disposable, prefilled insulin pen dosage device.
• 2001 Novo Nordisk acquires the controlling interest in the Brazilian pharmaceutical company Biobrás, the dominant insulin manufacturer in Brazil.
• 2002 NovoMix 30 FlexPen and NovoMix Penfill are introduced. NovoMix 30 is a dual-release insulin analogue.
• 2004 Levemir – a long-acting insulin analogue – is launched.
• 2005 Novo Nordisk announced that the company had moved into a leadership position in the U.S. insulin market for the first time ever based on the most recent data on total insulin volume.^[2]
• 2008 Novo Nordisk Canada Inc. was named one of Greater Toronto's Top Employers by Mediacorp Canada Inc. in October, which was announced by the Toronto Star newspaper.^[3]
• 2009 Novo Nordisk was named as an ethical leader of international business by think-tank Ethisphere.^[4]
• 2009 Novo Nordisk agrees to pay a $9 Million fine in connection with the payment of $1.4 million in kickbacks through the United Nations Oil-for-food Program.^[5]
• 2010 Victoza - the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes is approved for distribution in the US.^[6]
• 2010 Novo Nordisk pulls medicine from Greece due to price cuts triggered by the financial crisis in the country. The act caused uproar among diabetics and relatives.^[7]
• 2010 Novo Nordisk agreed to pay $25 million to the US government for illegally promoting its haemostasis management drug, NovoSeven.^[8]
• 2011 The Association of the British Pharmaceutical Industry reprimands Novo Nordisk for poor management due to breaching industry codes concerning various promotional efforts for its Victoza diabetes medicine.^[9]

• Hi TheOriginalSoni,

Here is the Novo Nordisk history in short and converted into prose. Will you add it to the article or should I?

Behind Novo Nordisk lies a story about two Danish firms - Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. Nordisk Insulinlaboratorium was founded by Hans Christian Hagedorn, August Krogh and August Kongsted in 1923 in Copenhagen.

In 1922, August Krogh and his wife Marie Krogh travelled to the US. The couple had heard reports of people with diabetes being treated with insulin – a hormone discovered in 1921 by two Canadians, Frederick Banting and Charles Best. Marie Krogh was a doctor herself and also had type 2 diabetes. The couple returned to Denmark with permission to manufacture and sell insulin in Scandinavia. With the economic help from August Kongsted – the owner of Leo Pharmaceutical Products - Insulin Leo was marketed in 1923.

When Krogh and Hagedorn started manufacturing insulin, they hired Thorvald Petersen and his brother Harald Pedersen to build the machines for insulin production. However, Thovald Pedersen was fired from Nordisk and the two brothers decided to try to manu-facture insulin themselves. Thorvald and Harald Pedersen managed to produce a stable liquid insulin and marketed Insulin Novo in 1925.. The brothers named their firm Novo Terapeutisk Laboratorium. Over the next decades the products were further improved, e.g. with focus on longer effect; nevertheless, there were still challenges to be met, and in the 1970s the new goal was to produce human insulin meaning that Novo would no longer depend on animal pancreases. In 1982, Novo succeeded and launched the world’s first insulin preparation identical to human insulin.

Nordisk marketed a genetically engineered human growth hormone in 1988 and Novo Nordisk is market leading in the world today in this area and introduced the world’s first liquid growth hormone in a pen system in 1999.

In 1989, Novo Industri A/S (Novo Terapeutisk Laboratorium) and Nordisk Gentofte A/S (Nordisk Insulinlaboratorium) merged to become Novo Nordisk A/S, the world's largest producer of insulin with headquarters in Bagsværd, Copenhagen. In 2000 the company demerged into NovoZymes A/S and Novo Nordisk A/S.

Research into bleeding disorders lead to the foundation of The Novo Nordisk Haemophilia Foundation in 2005 striving to improve access to care for people with haemophilia and allied bleeding disorders.

Kofod (talk) Kasper Kofod 14:09, 25 February 2015 (UTC)

I removed this paragraph, which can be readded using reliable sources. TheOriginalSoni (talk) 17:39, 7 November 2013 (UTC)

The company has also inaugurated the Novo Nordisk Changing Diabetes World Tour — a truck that folds out into an educational and awareness-developing bus. The vehicle was launched in Copenhagen in September 2005 and has visited Europe, Africa, Australia, Asia, the Indian subcontinent and the United States. The bus journey culminated in being stationed in New York City for the inaugural World Diabetes Day on November 14, 2007.^[10] In March 2015, NNIT was floated on the NASDAQ OMX Nordic.

In 2000, the enzymes business was separated and thus born Novozymes A/S, a spin out from Novo Nordisk A/S.

In 2015, the company announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate.^[11]

Jesper Brandgaard is the Executive Vice President and CFO of the global healthcare company Novo Nordisk A/S. Brandgaard has been the Vice Chairman of the board of directors in the Danish company SimCorp^[12] since 2007.^[13]

In January 2018, Reuters reported that Novo had offered to acquire Ablynx for $3.1 billion - having made an unreported offer in mid December for the company.^[14] However the Ablynx board rejected this offer the same day, saying that the price undervalued the business.^[15]

Products==

Ozempic® (semaglutide) is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of type 2 diabetes. The review of Ozempic® is based on the SUSTAIN programme, a global clinical development programme that comprises eight phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. The phase 3a programme involves a broad range of people with type 2 diabetes, including some with high cardiovascular risk profiles and people with and without renal disease. Ozempic® is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency.

Tresiba – a Diabetes mellitus type 1 and Type 2 diabetes drug. It is a new-generation basal insulin with ultra-long duration of action of more than 42 hours administered through subcutaneous injection. Intended to offer a flexible treatment and a good safety profile. It is approved and launched in the EU and Japan and under regulatory review in the US and other major markets.^[16]

Saxenda – a once-daily human GLP-1 analogue. It serves as an agonist, intended for combination with lifestyle changes (including diet), to offer sustainable weight loss for people with severe obesity, including those at particular risk of developing diabetes.^[16]

Ryzodeg – a drug for type 1 and 2 diabetes. Ryzodeg is a soluble co-formulation of Tresiba and NovoRapid, and is a rapid-acting mealtime insulin. It is approved to offer patients reduced risk of hypoglycemia and is currently approved in the EU and Japan. US FDA also approved Ryzodeg & Tresiba on 25 September 2015 after reviewing the interim safety data of the ongoing CV outcome trial DEVOTE .^[16]

Levemir – long-acting human insulin analogue for maintaining the basal level of insulin. It is an insulin analogue in which a fatty acid (myristic acid) is bound to the lysine amino acid at position B29. It is quickly absorbed after which it binds to albumin in the blood through its fatty acid at position B29. It then slowly dissociates from this complex.

Victoza – a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. It is an injectable drug developed for the treatment of type 2 diabetes.

NovoLog – a fast-acting insulin analog. It is a manufactured form of human insulin; where a single amino acid has been exchanged. This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream. As a result, it starts working in minutes, which allows one to take insulin and eat right away. Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus.

Novolin N – an intermediate-acting insulin given to help control the blood sugar level of people with diabetes.

Novolin R – is primarily used to treat high blood sugar levels in conditions like diabetes mellitus.

NovoLog Mix 70/30 – is a product which contains 30% insulin aspart and 70% insulin aspart protamine. The insulin aspart protamine portion is a crystalline form of insulin aspart, which delays the action of the insulin, giving it a prolonged absorption profile after injection. The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day.

In addition to the development of diabetes treatment pharmaceuticals, Novo Nordisk has been involved in the production of several lines of insulin pumps/pens for efficient delivery into the body and bloodstream.

NovoEight – is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A.

NovoSeven – is a form of blood factor VII that has been manufactured via recombinant technology.

- Jytdog (talk) 23:24, 8 February 2018 (UTC)

Novo A/S and Novo Nordisk are two separate companies. Novo A/S is today named Novo Holdings and is responsible for the investments of the Novo Nordisk Foundation. Novo Nordisk is not owner of Xellia Pharmaceutical.

The following Wikimedia Commons file used on this page or its Wikidata item has been nominated for speedy deletion:

• Nn logo rgb blue large.png

You can see the reason for deletion at the file description page linked above. —Community Tech bot (talk) 07:37, 11 March 2022 (UTC)

There are several news outlets covering payments made by Novo Nordisk to experts and groups in relation to its new drug. I don't write medical articles so I'll let others chose how to add it to the article.

• https://www.theguardian.com/business/2023/mar/12/revealed-experts-who-praised-new-skinny-jab-received-payments-from-drug-maker

Thanks

John Cummings (talk) 13:46, 12 March 2023 (UTC)

This article badly needs updating to reflect the impact of Ozempic and Wegovy on Novo Nordisk's recent success. At the moment, Ozempic is mentioned only once (on the sidebar) and Wegovy zero times. Given that these drugs are powering the company (and the Danish economy), this suggests that this article is in need of substantial revisions.

• https://www.nytimes.com/2023/08/28/business/denmark-ozempic-wegovy.html
• https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html

Rxtreme (talk) 21:57, 28 August 2023 (UTC)

You are correct, and you are the person to do it. Wasted Time R (talk) 01:20, 5 September 2023 (UTC)

The Novo logo is not a hieroglyph, it's a drawing. Xofg (talk) 00:46, 23 August 2024 (UTC)

It is also trivial and does not belong in the lead. Mihir.pethe1 (talk) 01:50, 10 September 2025 (UTC)

Section previously titled "Sponsorships and Pitchpeople" sounds self-interested. Considering the concern about WP:NPOV regarding payments for wp edits, I renamed to a more neutral title "Public Image" which could include both positive and negative information that meets notability and RS standards. Mihir.pethe1 (talk) 01:52, 10 September 2025 (UTC)

This edit request by an editor with a conflict of interest has now been answered. Set |answered=no to reactivate the request if necessary.

Hello! As part of my work for Beutler Ink, on behalf of our client Novo Nordisk, I'd like to request the following changes to this article:

• In the Introduction, update countries with production facilities from "9" to "13"

• Source: Per the company's 2024 annual report
• Reason: Makes outdated information current

• In the Introduction, change "affiliates or offices in five" to "affiliates in 80"

• Source: Per the company's 2024 annual report
• Reason: The article currently appears to be using the number of R&D locations. This corrects the inaccurate figure and makes it current.

• In the Introduction, change "specifically diabetes care medications" to "specifically diabetes and obesity care medications"

• Source: The article body
• Reason: This is a more accurate description of the Novo Nordisk's focus areas

• In the Controversies section, change "In September 2024, CEO Lars Fruergaard Jørgensen" to "In September 2024, then CEO Lars Fruergaard Jørgensen"

• Source: Article body, Infobox
• Reason: Clarifies that Jørgensen is no longer CEO.

Because I have a financial conflict of interest, I prefer not to make direct edits. If someone is willing to make these changes on my behalf, or give me a "Go ahead", I'd appreciate it. Always happy to discuss my requests, as well. Cheers, BINK Robin (talk) 18:35, 25 November 2025 (UTC)

Not done for now: Please provide sources for your 3rd and 4th suggested revisions. Refer to this page if you need help determining what sources can/cant be used. Mustbeotherwise (talk) 02:53, 26 January 2026 (UTC)

@Mustbeotherwise:, Whether it's beneficial to even include number of affiliates and factory locations especially when its only sourced to company's own site is debatable. I changed the CEO thing to timeless expression "CEO at the time". Graywalls (talk) 08:57, 6 February 2026 (UTC)

Partly done: I didn't do asks 1 and 2 as graywalls is probably right that stuff like that doesn't really matter. Point 4 was already done. I did 3, WP:skyblue   MetalBreaksAndBends   (talk) (contribs) 17:29, 6 February 2026 (UTC)

@Graywalls and MetalBreaksAndBends: Thanks for making those changes. Removing the number of affiliates and production facilities from the lede to simplify it and remove unnecessary detail makes sense to me. Is one of you willing to make that change? Cheers, BINK Robin (talk) 17:38, 9 February 2026 (UTC)

Looking at it, I think those parts have already been removed.   MetalBreaksAndBends   (talk) (contribs) 21:00, 9 February 2026 (UTC)

This edit request by an editor with a conflict of interest has now been answered. Set |answered=no to reactivate the request if necessary.

Hi editors, I'm Robin and I work for Beutler Ink on behalf of Novo Nordisk. I'd like to propose a substantial overhaul of the content in this article, taken in smaller chunks so as not to be too overwhelming.

One of the big challenges with this company is that its history is really the history of two companies. It is easy to conflate the two, especially around the time of the merger of Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium. The names are similar and they worked on similar projects. This conflation can be seen with some of the unclear language in the 1982–1994 section (e.g. it says the company did things in 1985 but there were in fact two companies until 1989).

I think the easiest way to follow the early history of Novo Nordisk is to treat it as two separate histories. I have a draft/diff that should make it easier to visualize what I am proposing. Restructuring the article will make the content as clear as it can be for readers and ensure accuracy throughout.

Taking this piece-by-piece will create some discombobulated text, especially in the early going but hopefully it will all come together and make sense, especially when viewed alongside the draft/diff I made.

Here's what I propose starting with:

Under the History heading, before any subheadings, add the following:

Novo Nordisk traces its origins to the 1920s with the founding of Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium.^[1]

Change the 1922-1925 subheading to Nordisk Insulin Laboratorium

Replace the first paragraph of 1922-1925 with the following:

August Krogh and his wife Marie became interested in insulin upon hearing about it while on an American lecture tour in 1923; they modified their itinerary to meet with insulin discoverers Frederick Banting, John Macleod, Charles Best, and James Collip.^{[1][2]: 43 [3]: 8} August Krogh received permission to produce insulin in Denmark; Krogh and physician and diabetes specialist Hans Christian Hagedorn, with funding and facilities support from August Kongsted, began experimenting with means of extracting and purifying insulin from fish and rabbit pancreases.^{[2]: 23, 26–27}

Known as the Insulin Laboratory, the research and production arm was operated as a unit of Kongsted's pharmaceutical company, Løvens Kemiske Fabrik.^[2]: 31 Kongsted rented a factory in Emdrup, Denmark, in late 1923 to help meet the demand for insulin. The Insulin Laboratory and the factory were spun off into a new company, Nordisk Insulin Laboratorium, in July 1924.^{[2]: 40, 43} The company was founded with an associated foundation and the three men served as the board of directors for both, with the foundation board membership barring them from profiting on the sale of insulin. The foundation and Nordisk Insulin signed articles of association in 1926 and the foundation received tax-exempt status by royal decree in January 1927.^{[2]: 43–45 [3]: 8–9}

References

1. [1]

   Lambert, Carmen; Delgado, Elias (27 February 2024). "100 Years since the Discovery of Insulin, from Its Discovery to the Insulins of the Future". Biomedicines. 12 (3). doi:10.3390/biomedicines12030533. Retrieved 15 April 2026.
2. [2]

   Jacobsen, Kurt (2023). Novo Nordisk. Gad Publishers. ISBN 9788712073901.
3. [3]

   Poulsen, Jacob E. (12 January 1975). "The Impact of August Krogh on the Insulin Treatment of Diabetes and our Present Status". Acta Medica Scandinavica. 197 (S578): 7–14. doi:10.1111/j.0954-6820.1975.tb06497.x. Retrieved 15 April 2026.

Textdiff to better visualize the changes:

This replacement replaces primary sources directly from Novo Nordisk with scholarly papers and a book written about the company by a professor at the University of Copenhagen. It fills out the early history and some missing details, as well as corrects the details on the establishment of the company and makes the language more encyclopedic and neutral in tone.

Please let me know what you think! I am happy to answer any questions that I can. I realize this relies heavily on a book editors may not have access to so I am happy to provide additional information where needed. Thanks in advance for your consideration. Cheers 18:04, 15 June 2026 (UTC) BINK Robin (talk) 18:04, 15 June 2026 (UTC)

When proposing a huge change, it helps to provide a diff that shows the changes.

https://en.wikipedia.org/w/index.php?title=User:BINK_Robin/Draft:Novo_Nordisk&diff=1359626919&oldid=1359540746 does this using the id of what are currently the latest version of the live page and of your version.

More than I am prepared to review. But this initial chunk looks good to me. ... but I hesitate to approve as it would lodge a foot in the door for a proposed COI edit that would replace 90-something percent of the article. RememberOrwell (talk) 23:29, 24 June 2026 (UTC)

Hi BINK Robin, I have implemented most of this request with some editing, and with retention of the sentence of the founding of Novo Terapeutisk Laboratorium for now, since the proposed change did not include an addition of that to the article (given the size of the draft, section-based proposals are best, but future proposals can tweak that part out. Best, Spencer^T•C 21:04, 23 July 2026 (UTC)

I'm curious - do you think it's appropriate for someone with a large FCoI to rewrite 9x% of an article? In general? (not just specifically-as we see at the diff I provided). It's my understanding that Wikipedians generally view accepting a 90%+ wholesale rewrite from a financially conflicted editor as entirely inappropriate. Per Template:Edit_COI/Instructions: "It is better not to propose major rewrites of articles or sections of articles where you have a conflict of interest. See WP:COI. The article must include any negative material or controversies found in reliable sources. Good reviewers will look for such omissions. Do not ask that negative material be removed if it is well-sourced and accurate." (To be clear: I'm not complaining about your edit. Concerned what's next. ) NN has interesting origins. RememberOrwell (talk) 04:42, 27 July 2026 (UTC)

I fully agree with the need for close review of any COI edit, regardless of length. I did not have significant concerns about this proposed edit, but without reviewing other sections - which sound like have not yet been proposed - it would be hard for me to say one way or the other. It will be interesting to see how the company went from "foundation board membership barring them from profiting on the sale of insulin" to making billions in profit but the current article does not explain this either. Spencer^T•C 15:32, 27 July 2026 (UTC)

Other sections have been proposed - again, https://en.wikipedia.org/w/index.php?title=User:BINK_Robin/Draft:Novo_Nordisk&diff=1359626919&oldid=1359540746 is the proposed overall change, it's just one paragraph of it was presented directly on this page. So do you now see why my questions are appropriate? I see someone with a large FCoI rewriting 9x% of the article. RememberOrwell (talk) 19:13, 29 July 2026 (UTC)

@Spencer: thanks for reviewing! The only question I had was about the 1922–1925 heading. Did you prefer to retain that heading? I had proposed changing it to Nordisk Insulin Laboratorium. I will request the other sections as sections as well. Thanks again! BINK Robin (talk) 14:59, 27 July 2026 (UTC)

Given the retention of information related to Novo Terapeutisk Laboratorium as I mentioned above, it did not make sense with the current edit to change the section header from the current dates. Spencer^T•C 15:32, 27 July 2026 (UTC)

This edit request by an editor with a conflict of interest has now been answered. Set |answered=no to reactivate the request if necessary.

Hi editors, for my next request I propose adding the following immediately after the foundation received tax-exempt status by royal decree in January 1927:

This is the remainder of the Nordisk Insulin Laboratorium section I had started work on with my last request. I am putting the entire section out at the suggestion of Spencer.

This gives a complete overview of the early history of Nordisk Insulin Laboratorium, filling in a large gap in the history of the company. Once again, this relies heavily on a book that may be difficult to access, so I am happy to provide any additional information I can where needed. Cheers! BINK Robin (talk) 15:04, 27 July 2026 (UTC)

Hi BINK Robin, the major source for this section Novo Nordisk by Kurt Jacobsen from a Danish publisher, and appears to have been originally published in the Danish language. I'm not sure if there are alternative accessible sources that can be used for some of the information. I double checked the state-wide university library catalog within my state, as well as the inter-library loan system (also covering public library systems throughout my state), and the title is not available. Maybe others will have better luck in another location, so will defer to another reviewer, but it will be difficult to do appropriate review of a requested COI edit with an unavailable reference serving as the near exclusive source. Although this was partially an issue with the initial request, the Acta medica Scandinavica article was available via inter-library loan, with the Biomedicines article available online. Of note, the above request notes that Novo continued to collaborate with the Nazis, but in the extended draft you linked elsewhere, this is not mentioned or further characterized within the Novo sub-section. One Substack of unclear verifiability—IMO, not good enough to use as a soruce here—notes, "During World War II's Nazi occupation, Novo supplied occupied Europe under orders, boosting scale but raising ethical questions (post-war, the Danish state reclaimed profits", so evidently there would be something worth mentioning in the Novo subsection. Spencer^T•C 16:13, 27 July 2026 (UTC)

@Spencer: thanks for the feedback! I thought the book might be a bit of a challenge. I have a PDF of the English translation that I have been using for my research. I could provide direct quotes if that would be helpful, and I will check around myself and see if it exists elsewhere online or if there might be a way to share it without breaking copyright rules. If only subreferencing was active on English Wikipedia! As for Novo and supplying Europe under the Nazi regime, I will look back in the book and see what I can come up with to flesh that out more in the extended draft. BINK Robin (talk) 18:13, 27 July 2026 (UTC)

IMO most of the issue isn't necessarily what you have referenced to the book, but rather is there information covered in the book that isn't included here (i.e. information about Novo during Nazi Germany/WWII era) and it is difficult to assess for neutrality with only select quotations provided from the book. Best, Spencer^T•C 21:13, 27 July 2026 (UTC)

@Spencer: I completely understand. It looks like the print book is only in a few libraries in the USA, and is available for purchase in audiobook format. There is also Storytel, which has both the audiobook and English ebook but it is a subscription service. Interestingly, not even the publisher has it in stock. I have the PDF, but aside from sharing quotes I am not sure what the best way is to get the whole text to you or another editor for a broader review without violating copyright rules. What do you think? BINK Robin (talk) 16:07, 28 July 2026 (UTC)

@BINK Robin: Thank for the Worldcat link. With that information, I have put a request via my local public library for a copy via InterLibrary Loan. It's unknown if they will be able to obtain the book but they will let me know, hopefully in the next week or two. It may take 2-6 weeks to arrive, and if there is a cost more than a nominal fee, that won't work as well. If any other editors have closer access to the US Library of Congress or other university libraries is able to take a look at the request in the meantime, you are more than welcome. Best, Spencer^T•C 18:20, 28 July 2026 (UTC)

@Spencer: Thanks, I really appreciate your time and effort here. Hopefully they can get it! BINK Robin (talk) 19:29, 28 July 2026 (UTC)

Looping back, I have not heard anything from my library in the past 3 weeks, so I am doubtful that I will be able to get access to this book. Will let you know if that changes, but would defer to another editor who may be able to access the resoure. Best, Spencer^T•C 02:46, 20 August 2026 (UTC)

Thanks for following up and looking into it! I really appreciate it. I wish there was a better way to get the copy of the PDF to you. I'll let you know if I figure out any other options for access. In any case, thanks again! BINK Robin (talk) 16:24, 20 August 2026 (UTC)

The user below has a request that an edit be made to Novo (company). That user has an actual or apparent conflict of interest. Summary of request: updating more modern history The requested edits backlog is very high. Please be extremely patient. There are currently 907 requests waiting for review. Please read the instructions for the parameters used by this template for accepting and declining them, and review the request below and make the edit if it is well sourced, neutral, and follows other Wikipedia guidelines and policies. Remember to set the |answered= parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input.

Hi editors, while Spencer checks in on getting access to the Novo Nordisk book, I thought I would post the requests I had for the more accessible sections.

I propose replacing the second paragraph of 1982–1994 with the following:

Why do this?

• Two sentences in the paragraph are not about Novo Nordisk
• The only sources used in this paragraph are primary sources
• One sentence is uncited
• The replacement text uses reliable secondary sourcing

I found the Scandinavian Review source through ProQuest, which from my understanding should mean it is accessible to anyone with access to The Wikipedia Library.

This also creates redundancy with the first paragraph of 2000–2018, so it may be prudent to remove that paragraph as well. @Spencer:, pinging you in case you are interested in taking a look at this request given your reviews of my past requests on this article.

Let me know what you think! Cheers, BINK Robin (talk) 22:18, 19 August 2026 (UTC)

The infobox of the article does not feature the current logo of the company. The current logo can bee seen here:

• https://www.novonordisk.com/content/dam/nncorp/global/en/media/images/latest-news/novo-logo-white.jpg.corpimgw.2000.2000.jpg
• https://www.novonordisk.com/news-and-media/latest-news/lasting-health-starts-now.html

~2026-49262-03 (talk) 01:06, 16 September 2026 (UTC)

New logo has been added to the article. --Trjxikvh3000 (talk) 02:38, 27 September 2026 (UTC)

At the top of the article, there is a notice box that begins with the text: "This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view." Which parts of the article were written in violation of Wikipedia's terms of use?

I can see from this talk page that a user named "BINK Robin", who works for a communications agency (I guess), frequently requests changes. However, requesting changes on the article's talk page would not in itself constitute "a violation of Wikipedia’s terms of use", would it? So what exactly is problematic about the article? Trjxikvh3000 (talk) 00:46, 28 September 2026 (UTC)

The “Research and Pipeline” section of the article contains three paragraphs about abandoned/failed initiatives by Novo. The section says nothing about Novo being the inventor of Semaglutide. The section is in no way promotional, but rather quite negative. Trjxikvh3000 (talk) 13:40, 3 October 2026 (UTC)

The “Legal Issues” section, as far as I can see, contains only information about legal cases in which Novo has lost or been criticized. There is no information about legal cases won by Novo. Trjxikvh3000 (talk) 13:43, 3 October 2026 (UTC)

I can see from the article’s history that, after the tag/template was added to the article, various contributors have worked to improve it. Very large sections of text have been removed because they were considered promotional. What is the reason that the tag/template is still in the article? I cannot see any justification for it. Trjxikvh3000 (talk) 13:52, 3 October 2026 (UTC)